National Institute of Allergy and Infectious Diseases
  National Institutes of Health
NIAID Home Health & Science Research Funding Research News & Events Labs at NIAID About NIAID

Food Allergy
 Understanding
 Research
 Clinical Practice Guidelines
  What is a Clinical Practice Guideline?
  Who Writes and Reviews Clinical Guidelines?
  Process
  Coordinating Committee
  Expert Panel
  Key Events
  Limitations
  Financial Disclosure
  Meeting Summaries


Food Allergy

Clinical Practice Guidelines

Financial Disclosure

The disclosure and management of real or perceived potential financial conflicts of interest are a critical step in building public trust in clinical guidelines. To that end, the NIAID has established a procedure that insures maximum transparency of the guidelines development process by reporting the affiliations and activities of members of the Expert Panel. See the Expert Panelists.

Financial and Other Disclosures

  • Dr. Bahna has received funding/grant support from Genentech.
  • Dr. Beck has received funding/grant support from the AAAAI, the National Eczema Association, and the NIH.
  • Dr. Boyce has served on the Advisory Board of GlaxoSmithKline. He has served as a consultant and/or speaker for Altana, GlaxoSmithKline, and Merck. He has received funding/grant support from the NIH.
  • Dr. Burks holds, or is listed as an inventor on, multiple U.S. Patents related to Food Allergy. He owns stock in Allertein and MastCell, Inc and is a minority stockholder in Dannon Co. Probiotics. He has served as a consultant for ActoGeniX NV, McNeil Nutritionals, Mead Johnson, and Novartis. He has served on the speaker’s bureau for EpiPen/Dey, L.P., and has served on the data monitoring committee for Genentech. He has served on an expert panel for Nutricia. Dr. Burks has received funding/grant support from the Food Allergy and Anaphylaxis Network, Gerber, Mead Johnson, and the NIH.
  • Dr. Camargo has consulted for Dey and Novartis. He has received funding/grant support from a variety of Government agencies and not-for-profit research foundations, as well as Dey and Novartis.
  • Dr. Eichenfield has received funding/grant support from a variety of not-for-profit foundations, as well as Astellas, Ferndale, Johnson & Johnson, Novartis, Sinclair, Stiefel, and Therapeutics Inc.
  • Dr. Furuta has served as a consultant and/or speaker to Ception Therapeutics and TAP. He has received funding/grant support from the American Gastrointestinal Association and the NIH.
  • Dr. Hanifin has served as served as a consultant for ALZA, Anesiva, Inc, Barrier Therapeutics, Inc, Milliken & Company, Nordic Biotech, Novartis Pharmaceuticals Corporation, Shionogi USA, Taisho Pharmaceutical R&D, Inc, Teikoku Pharma USA, Inc, UCB, York Pharma, ZARS, Inc and ZymoGenetics. He has served as an investigator or received research funding from ALZA, Astellas Pharma US, Inc, Asubio Pharmaceuticals, Inc, Centocor, Inc, Corgentech, Novartis, Nucryst Pharmaceuticals, Seattle Genetics and Shionogi USA.
  • Dr. Jones has served as a speaker and grant reviewer and has served on the medical advisory committee for the Food Allergy and Anaphylaxis Network. She has received funding/grant support from Dyax, Corp, the Food Allergy and Anaphylaxis Network, Mead Johnson, the National Peanut Board and the NIH.
  • Dr. Kraft has served as a consultant and/or speaker for Astra-Zeneca, Genentech, GlaxoSmithKline, Merck, Novartis, and Sepracor. She has received funding/grant support from Genentech, GlaxoSmithKline, the NIH and Novartis.
  • Dr. Levy has no relevant financial interests.
  • Dr. Liacouras has served as a consultant and/or speaker to AstraZeneca, Merck, Nutrica, TAP, and Wyeth. He holds stock in Ception Therapeutics.
  • Dr. Lieberman has served as a consultant and/or speaker to Dey Laboratories, Novartis, Schering-Plough, AstraZenica, Merck, TEVA, Pfizer, MEDA, Alcon, Genentech, Intelliject, and the Food Allergy and Anaphylaxis Network. He is past president of the American Academy of Allergy, Asthma, and Immunology.
  • Dr. Luccioli has no relevant financial interests.
  • Ms. McCall has no relevant financial interests.
  • Dr. Sampson holds, or is listed as an inventor on, multiple U.S. Patents related to Food Allergy. He owns stock in Allertein Therapeutics. He is the President of the American Academy of Allergy, Asthma and Immunology. He has served as a consultant for Allertein Therapeutics, the American Academy of Allergy, Asthma and Immunology, the Food Allergy Initiative, and Schering Plough. He has received funding/grant support for research projects from the Food Allergy Initiative, the NIH (DRR, NIAID, NCCAMS), and Phadia AB. He is a co-owner of Herbal Spring, LLC.
  • Dr. Ronald Simon has served as a speaker for Dey Laboratories, Genentech, GlaxoSmithKline, Merck, Novartis, and the U.S. FDA.
  • Dr. Estelle Simons holds a patent on “Fast-disintegrating epinephrine tablets for sublingual administration.” She is a past-President of the American Academy of Allergy, Asthma, and Immunology and of the Canadian Society of Allergy & Clinical Immunology. She is a member of the Advisory Boards of Dey, Intelliject, and ALK-Abello. She has received funding/grant support from AllerGen, the Canadian Allergy, Asthma and Immunology Foundation/Anaphylaxis Canada, and the Canadian Institutes of Health Research.
  • Dr. Stein has received funding/grant support from the U.S. Centers for Disease Control and the U.S. Department of Agriculture.
  • Dr. Teach has served as a speaker for AstraZeneca. He has received funding/grant support from the AstraZeneca Foundation, Aventis, the Child Health Center Board, the CNMC Research Advisory Council, the National Association of Chain Drug Stores Foundation, the NIH (NIAID, NHLBI), Novartis/Genentech, the Robert Woods Johnson Foundation, the U.S. CDC, the U.S. Public Health Service, and the Washington D.C. Department of Health.
  • Dr. Yawn has no relevant financial interests.
  • Dr. Zeiger is a consultant and receives grant support from Genentech for activities related to asthma

back to top

E-mail Icon E-mail this page
Print Icon Print this page